Bioceltix S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-08-13
Share capital
538,225.30 PLN
Activity description

Bioceltix is a Polish biotechnology company that develops innovative veterinary biological drugs, specifically using allogenic stem cells to treat conditions such as osteoarthritis in dogs and atopic dermatitis in both dogs and horses. The company focuses on immunomodulatory therapies targeting inflammatory and autoimmune diseases, adhering to high pharmaceutical quality standards. Bioceltix is also advancing a research project for a cell-free biological drug aimed at treating atopic dermatitis in dogs.

Registered address
ul. Bierutowska 57-59/Bud.iii, 51-317 Wrocław, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-21907-79452-GJCCI-09

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 33 days early. All were audited by a statutory auditor.

  • 202503/07/2026
  • 202418/06/2025
  • 202326/06/2024
  • 202207/07/2023
  • 202124/06/2022
  • 202028/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 67.10
-1.70 (-2.47%)
67.0068.0069.0067.1010:0012:0014:0016:00
Open
PLN 68.70
High
PLN 69.00
Low
PLN 66.30
Volume
3.02K
Avg. vol.
4.18K
Market cap
PLN 371.21M
P/E ratio
–
EPS
-PLN 3.35
Shares outstanding
5.53M
52-week
PLN 65.00 – 72.00
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD -17.56kUSD -1.36mUSD -1.37m
Q1 2026USD 1.89kUSD -1.56mUSD -1.53m
Q4 2025USD 0.00USD -857.86kUSD -850.33k
Q3 2025USD 0.00USD -1.12mUSD -1.10m

Results for Q3 2026:Nov 27, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 25%
Top 23%
City · Wrocław4,512 / 13,650
Top 33%
Voivodeship · Dolnośląskie8,771 / 23,831
Top 37%
Country · Poland112,924 / 297,069
Top 38%

Results vs industry

Revenue
This companyUSD 616.32kMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -3.81mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 4.35mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 18.99mMedianUSD 281.58kAverageUSD 8.35m

Authorized Representatives

Andrij Włach age 43 – Attorney-in-fact (joint)
Łukasz Piotr Bzdzion age 44 – President of the Management Board
Grzegorz Ostropolski age 50 – Attorney-in-fact (joint)
Paweł Wielgus age 46 – Management Board Member

Manner of representation

In the case of a one-person management board, the President of the Management Board is authorized to make declarations and sign on behalf of the company independently. In the case of a multi-member management board, joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy, is required to make declarations and sign on behalf of the company.

Supervisory board

Wojciech Aksman age 49 – Supervisory Board Member
Beata Bożena Porowska age 57 – Supervisory Board Member
Ewelina Pawlus-Czerniejewska – Supervisory Board Member
Ewa Więcławik age 35 – Supervisory Board Member
Michał Jank age 52 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2016-08-30.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jun 1, 2021Shareholders' meeting convened
Dec 29, 2020Shareholders' meeting convened
Jul 8, 2020Shareholders' meeting convened

Public aid

15 public aid cases recorded, with a total value of $17,294,925.

PurposeGross amount
Aid for research and development projects: industrial research
$1.4M
Aid for research and development projects: experimental development
$479.1K
Regional investment aid
$4.4M

European Funds

5 projects co-financed from European Funds recorded, with total EU co-financing of $12,633,260.

ProjectEU co-financing
Innovative cell-free biological medicine for veterinary applications (InnoBioVet)
$3.8M
Construction and commissioning of a pharmaceutical manufacturing plant for innovative advanced therapy veterinary medicinal products
$4.3M
Development of a biological veterinary medicinal product BCX-CM-AD for the treatment of atopic dermatitis in dogs
$2.5M

Competitors

Name
JJP Biologics sp. z o.o.
Captor Therapeutics S.A.
Fileclo sp. z o.o.
Precisionlife Poland sp. z o.o.
Famicordtx S.A.
Human Biome S.A.
VET Cell Tech sp. z o.o.
Vaxican sp. z o.o.
Vasa Therapeutics sp. z o.o.
Multiqure S.A.

Change history

DateEvent
2025-11-06Share capital increase
2025-08-26Switch to PKD 2025
2024-06-27Share capital increase
2023-07-03Share capital increase
2023-04-28Share capital increase

FAQ

Last updated: 2026-10-07